Real-world evidence for romosozumab in high-risk fracture patients

UCB (Euronext: UCB), Belgium’s largest pharma company, has announced findings from a collection of real-world evidence studies to reaffirm the effectiveness and clinical impact of romosozumab, the only dual-acting osteoporosis treatment that increases bone formation and decreases bone resorption, around the world.

The data were presented as a poster at the 25th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2025 in Rome, Italy.

Romosozumab, trade-named Evenity, was developed and is co-marketed with US biotech Amgen (Nasdaq: AMGN). It was approved in the European Union in December 2019 for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.